U.S. researchers who cultivated beta-amyloid fibrils using tissue from the brains of two Alzheimer's patients with distinct levels of brain damage and medical histories found the protein from each patient had different molecular structures. The findings could lead to the development of personalized diagnostic and treatment strategies, researchers reported in the journal Cell.

Full Story:

Related Summaries